CARBIDOPA AND LEVODOPA

Post-LOE

carbidopa and levodopa

Ascentage Pharma
ANDAORALTABLET
Approved
Jan 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1

Mechanism of Action

DOPA Decarboxylase Inhibitors

Pharmacologic Class:

Aromatic Amino Acid

Indications (8)

the treatment of Parkinson's diseasepost-encephalitic parkinsonismsymptomatic parkinsonismmanganese intoxicationParkinson's diseasenauseavomitingpermit more rapid titration of levodopa

Clinical Trials (1)

NCT01533116Phase 1Completed

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Started Mar 2009
Company
Ascentage Pharma
Ascentage Pharma
China - Beijing
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers